InsiderTrades.com logo
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
From Autonomix   |   Ad
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.

IOBT Insider Trading

Insider Ownership Percentage: 3.50%
Insider Buying (Last 12 Months): $6,062,948.60
Insider Selling (Last 12 Months): $0.00

IO Biotech Insider Trading History Chart

This chart shows the insider buying and selling history at IO Biotech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

IO Biotech Share Price & Price History

Current Price: $1.22
Price Change: ▼ Price Decrease of -0.1 (-7.58%)
As of 11/29/2023 01:00 AM ET

This chart shows the closing price history over time for IOBT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
From Autonomix   |   Ad
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.

IO Biotech Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/21/2023Brian BurkavageCAOBuy5,000$0.99$4,950.006,500View SEC Filing Icon  
8/9/2023Vivo Capital Ix, LlcMajor ShareholderBuy3,157,894$1.90$5,999,998.603,157,894View SEC Filing Icon  
3/17/2023Amy SullivanCFOBuy25,000$2.32$58,000.0025,000View SEC Filing Icon  
See Full Table
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
From Autonomix   |   Ad
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.

SEC Filings (Institutional Ownership Changes) for IO Biotech (NASDAQ:IOBT)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at IOBT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

IO Biotech Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/15/2023Armistice Capital LLC2,148,000$3.03M0.0%N/A3.260%Search for SEC Filing on Google Icon
11/14/2023Stonepine Capital Management LLC1,975,308$2.79M0.9%N/A2.998%Search for SEC Filing on Google Icon
11/14/2023Pivotal bioVenture Partners Investment Advisor LLC864,197$1.22M0.5%N/A1.312%Search for SEC Filing on Google Icon
11/8/2023Vivo Capital LLC6,173,439$8.71M1.1%+104.7%9.371%Search for SEC Filing on Google Icon
8/15/2023Citadel Advisors LLC37,690$74K0.0%-19.5%0.131%Search for SEC Filing on Google Icon
8/14/2023Two Sigma Securities LLC13,020$25K0.0%N/A0.045%Search for SEC Filing on Google Icon
8/11/2023Renaissance Technologies LLC69,100$0.14M0.0%+12.0%0.240%Search for SEC Filing on Google Icon
7/25/2023Summit Trail Advisors LLC43,744$86K0.0%N/A0.152%Search for SEC Filing on Google Icon
5/12/2023Renaissance Technologies LLC61,700$0.12M0.0%+155.0%0.214%Search for SEC Filing on Google Icon
2/15/2023Millennium Management LLC20,554$47K0.0%-46.4%0.071%Search for SEC Filing on Google Icon
2/15/2023Morgan Stanley29,060$67K0.0%+31.7%0.101%Search for SEC Filing on Google Icon
2/14/2023RA Capital Management L.P.1,127,260$2.59M0.1%-39.3%3.911%Search for SEC Filing on Google Icon
2/13/2023Renaissance Technologies LLC24,200$56K0.0%+31.4%0.084%Search for SEC Filing on Google Icon
2/10/2023Bank of America Corp DE1,854,185$4.27M0.0%+18,441.9%6.434%Search for SEC Filing on Google Icon
11/15/2022Citadel Advisors LLC42,180$0.11M0.0%+192.4%0.146%Search for SEC Filing on Google Icon
11/14/2022Renaissance Technologies LLC18,423$50K0.0%N/A0.064%Search for SEC Filing on Google Icon
11/14/2022Psagot Value Holdings Ltd. Israel40,846$0.11M0.0%N/A0.142%Search for SEC Filing on Google Icon
11/2/2022Victory Capital Management Inc.43,741$0.12M0.0%N/A0.152%Search for SEC Filing on Google Icon
8/15/2022Millennium Management LLC46,231$0.22M0.0%-36.4%0.160%Search for SEC Filing on Google Icon
5/17/2022Jane Street Group LLC14,280$76K0.0%N/A0.050%Search for SEC Filing on Google Icon
5/13/2022Ergoteles LLC11,126$59K0.0%N/A0.039%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.62,234$0.33M0.0%-69.7%0.216%Search for SEC Filing on Google Icon
2/15/2022Samsara BioCapital LLC1,120,437$7.17M1.4%N/A3.888%Search for SEC Filing on Google Icon
2/15/2022Capital World Investors1,235,000$8.11M0.0%N/A4.286%Search for SEC Filing on Google Icon
2/14/2022Soleus Capital Management L.P.672,734$4.31M0.4%N/A2.335%Search for SEC Filing on Google Icon
2/14/2022Novo Holdings A S3,277,932$20.98M1.0%N/A11.376%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
IO Biotech logo
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Read More on IO Biotech

Today's Range

Now: $1.22
Low: $1.12
High: $1.34

50 Day Range

MA: $1.12
Low: $0.85
High: $1.54

52 Week Range

Now: $1.22
Low: $0.82
High: $3.31

Volume

146,616 shs

Average Volume

124,422 shs

Market Capitalization

$80.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of IO Biotech?

IO Biotech's top insider investors include:
  1. Vivo Capital Ix, Llc (Major Shareholder)
  2. Amy Sullivan (CFO)
  3. Brian Burkavage (CAO)
Learn More about top insider investors at IO Biotech.

Who are the major institutional investors of IO Biotech?

IO Biotech's top institutional investors include:
  1. Vivo Capital LLC — 9.37%
  2. Armistice Capital LLC — 3.26%
  3. Stonepine Capital Management LLC — 3.00%
  4. Pivotal bioVenture Partners Investment Advisor LLC — 1.31%
Learn More about top institutional investors of IO Biotech stock.

Which institutional investors are buying IO Biotech stock?

In the previous quarter, IOBT stock was purchased by institutional investors including:
  1. Vivo Capital LLC
  2. Armistice Capital LLC
  3. Stonepine Capital Management LLC
  4. Pivotal bioVenture Partners Investment Advisor LLC
In the last year, these company insiders have bought IO Biotech stock:
  1. Vivo Capital Ix, Llc (Major Shareholder)
  2. Amy Sullivan (CFO)
  3. Brian Burkavage (CAO)
Learn More investors buying IO Biotech stock.
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
From Autonomix   |   Ad
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Invest in Autonomix today.